
Jazz Pharmaceuticals rose 31.0% from $175.74 to $230.26, ahead of the S&P 500's +5.7%. Its worst day was Jan 8 (−5.4%), and its low came Jan 8 at $160.25.
Nov 20, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data
−5.3% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Jazz Pharmaceuticals closed at its lowest level of the year, 8.8% below where the year started.
−5.4%, the year's worst day · S&P 500 0.0%
EPS of $6.64 beat the $6.16 estimate on $1.2B revenue (est. $1.2B); FY revenue guidance of $4.3B–$4.5B against the $4.4B consensus.
+13.2%, the year's best day, on 6M shares, the year's heaviest volume · S&P 500 +0.8%
EPS of $6.34 beat the $4.49 estimate on $1.6B revenue (est. $977.6M); FY revenue guidance of $4.3B–$4.5B against the $4.5B consensus.
+7.7% · S&P 500 +1.4%
EPS of $5.71 missed the $5.94 estimate on $1.2B revenue (est. $1.1B); FY revenue guidance of $4.6B–$4.8B against the $4.5B consensus.
+4.0% · S&P 500 +1.8%
EPS of $-3.88 missed the $-2.80 estimate on $1.2B revenue (est. $1.2B); FY revenue guidance of $4.8B–$4.8B against the $4.7B consensus.
+7.1% · S&P 500 +0.3%
Where it ended: a close of $230.26 on Nov 20, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $6.50, revenue est. $1.3B).
Nothing in the past 12 months.
All JAZZ dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for JAZZ and SPY from Benzinga historical bars. Not investment advice.